Akèy › Atrofi miskilè spinal
Etid klinik pou Atrofi miskilè spinal ap rekrite nan Etazini
23 etid pou Atrofi miskilè spinal ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- New York City, NY9 etid
- Mountain View, CA8 etid
- Philadelphia, PA7 etid
- Norfolk, VA6 etid
- Grand Rapids, MI6 etid
- Chicago, IL6 etid
- Boston, MA5 etid
- Houston, TX5 etid
- Phoenix, AZ4 etid
- Lewisville, TX4 etid
- Memphis, TN4 etid
- Aurora, CO4 etid
- Little Rock, AR4 etid
- Orange, CA3 etid
- Orlando, FL3 etid
- Harrisburg, PA3 etid
- Charlottesville, VA3 etid
- Durham, NC3 etid
- Portland, OR3 etid
- Minneapolis, MN3 etid
- Atlanta, GA3 etid
- Fort Worth, TX3 etid
- Gainesville, FL3 etid
- Dallas, TX3 etid
- Cedar Rapids, IA3 etid
- Columbia, MO3 etid
Pa eta
- Arizona4 etid
- Arkansas4 etid
- Colorado4 etid
- Florid8 etid
- Georgia3 etid
- Illinois6 etid
- Iowa3 etid
- Kalifòni10 etid
- Massachusetts6 etid
- Michigan6 etid
- Minnesota3 etid
- Missouri4 etid
- New York10 etid
- North Carolina3 etid
- Oregon3 etid
- Pennsylvania8 etid
- Tennessee4 etid
- Texas10 etid
- Virginia7 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Registry of Cases of Spinal Muscular Atrophy
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Sep 30, 2026 · NCT07805278ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)
Ap rekriteFaz 4
Laj 2 a 100 · Tout sèks · Mizajou Sep 18, 2026 · NCT07448610A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
Ap rekriteFaz 2
Jiska laj 2 · Tout sèks · Mizajou Sep 14, 2026 · NCT07047144A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
Ap rekriteFaz 2
Laj 5 a 17 · Tout sèks · Mizajou Sep 14, 2026 · NCT07287982A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
Ap rekriteFaz 4
3 Months – 24 Months · Tout sèks · Mizajou Sep 10, 2026 · NCT05861999A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
Ap rekriteFaz 1
Laj 3 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06555419A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
Ap rekriteFaz 4
3 Months – 24 Months · Tout sèks · Mizajou Sep 3, 2026 · NCT05861986Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)
Ap rekrite
Laj 18 a 80 · Tout sèks · Mizajou Sep 2, 2026 · NCT07521930Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
Ap rekrite
Laj 3 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT05866419A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
Ap rekriteFaz 3
0 Days – 42 Days · Tout sèks · Mizajou Aug 18, 2026 · NCT07221669A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec
Ap rekriteFaz 3
0 Days – 7 Months · Tout sèks · Mizajou Aug 11, 2026 · NCT07444450Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed Therapies
Ap rekriteEtid obsèvasyon
Laj 5 a 20 · Tout sèks · Mizajou Jul 9, 2026 · NCT06532474Clinical Procedures to Support Research in ALS
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jun 15, 2026 · NCT03489278ALS/MND Natural History Study Data Repository
Ap rekriteEtid obsèvasyon
Laj 18 a 90 · Tout sèks · Mizajou May 20, 2026 · NCT05966038Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA
Ap rekriteEtid obsèvasyon
Laj 12 ak plis · Tout sèks · Mizajou May 14, 2026 · NCT06955897A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
Ap rekriteFaz 3
Laj 15 a 60 · Tout sèks · Mizajou Apr 21, 2026 · NCT07444476Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 5 ak plis · Tout sèks · Mizajou Apr 9, 2026 · NCT06839469HABIT-ILE + FST in Children With SMA: Preliminary Effectiveness
Ap rekrite
Laj 5 a 17 · Tout sèks · Mizajou Mar 23, 2026 · NCT07488338Gait and Bone Health in SMA
Ap rekriteEtid obsèvasyon
Laj 8 a 50 · Tout sèks · Mizajou Mar 18, 2026 · NCT07400198Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Mar 17, 2026 · NCT07478172A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies
Ap rekriteEtid obsèvasyon
Laj 18 a 54 · Fanm · Mizajou Mar 9, 2026 · NCT05789758Diagnostic Journey, Patient Experience, and Disparities in the Treatment of Spinal Muscular Atrophy (SMA) in the MedStar Health System
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jan 16, 2026 · NCT07223489Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jan 31, 2025 · NCT04174157Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.